SKLB1608

SKLB1608 is a novel, orally bioavailable multi-target tyrosine kinase inhibitor (TKI) developed by the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University. It primarily targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Fibroblast Growth Factor Receptor 1 (FGFR1), and Platelet-Derived Growth Factor Receptor beta (PDGFRβ). By inhibiting these kinases, SKLB1608 exerts potent anti-angiogenic and anti-tumor effects, disrupting the signaling pathways essential for tumor vascularization and proliferation. It is currently being evaluated in clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC).